Bitdeer Technologies Option Alert: Mar 21 $7.5 Calls at the Bid: 1443 vs 11553 OI; Earnings 2/25 Before Open 

Bitdeer Technologies Option Alert: Mar 21 $7.5 Calls at the Bid: 1443 @ $7.47 vs 11553 OI; Earnings 2/25 Before Open Ref=$14.94

Bitdeer Technologies 株価情報 (NASDAQ: BTDR)

Bitdeer Technologies (NASDAQ:BTDR) 株価情報

Bitdeer Technologies

Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.

Bitdeer Technologies Group - Ordinary Shares

Bitdeer Technologies Group

Valvoline Receives Second Request From Federal Trade Commission For Additional Information About The Proposed Acquisition Of Breeze Autocare

News

Contracts

Movers

Trading Ideas

BON Wins $12M 24-Month Supply Agreement To Co-Develop Apple Polyphenol-Infused Health Solutions

Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRBW#NASDAQ">NTRBW</a>), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA&#x2122; abuse deterrent transdermal technology.
The Macao Intellectual Property Office granted patent J/9010 on February 11, 2025 as recorded in Macao Official Bulletin No. 10 on March 5, 2025. Macao is a Special Administrative Region (SAR) of the People's Republic of China that has its own patent system and patent laws which are separate and distinct from those of mainland China.
The AVERSA&#x2122; abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia as well as two regions of China: Hong Kong and Macao.
Nutriband's AVERSA&#x2122; abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA&#x2122; abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA&#x2122; Fentanyl, which incorporates Nutriband's AVERSA&#x2122; abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.

Government

Regulations

NTRB

NTRBW

Nutriband Secures Macao Patent for AVERSA, Expanding Global Protection for Abuse-Deterrent Opioid Patch, Eyes Up to $200M in Peak US Sales

Mizuho analyst David Belinger initiates coverage on Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform rating and announces Price Target of $105.

Price Target

Initiation

Analyst Ratings

Mizuho Initiates Coverage On Walmart with Outperform Rating, Announces Price Target of $105

General

ITGR

Integer Holdings Issues Statement On Tariffs, Says 'We continue to estimate an impact of $1 to $5 million on full year adjusted operating income, consistent with previous communications.'

Mizuho analyst David Belinger initiates coverage on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Neutral rating and announces Price Target of $975.

COST

Mizuho Initiates Coverage On Costco Wholesale with Neutral Rating, Announces Price Target of $975

VERV

Verve Therapeutics Receives FDA Fast Track Designation For Its VERVE-102 In Vivo Base Editing Medicine Targeting PCSK9

Biotech

CATX

Perspective Therapeutics Doses First Patient With [212Pb]VMT01 Monotherapy At 1.5 mCi In Phase 1/2a Study Of MC1R-Positive Metastatic Melanoma

Mizuho analyst David Belinger initiates coverage on Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral rating and announces Price Target of $92.

Mizuho Initiates Coverage On Target with Neutral Rating, Announces Price Target of $92

WIIM

JPMorgan Chase shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

Morgan Stanley analyst Kristine Liwag downgrades Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) from Overweight to Equal-Weight and lowers the price target from $10 to $7.

Downgrades

JOBY

Morgan Stanley Downgrades Joby Aviation to Equal-Weight, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Buy and maintains $7.5 price target.

Reiteration

UNCY

HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $7.5 Price Target

Earnings

JPMorgan Chase CEO Jamie Dimon: "The economy is facing considerable turbulence (including geopolitics), with the potential positives of tax reform and deregulation and the potential negatives of tariffs and "trade wars," ongoing sticky inflation, high fiscal deficits and still rather high asset prices and volatility."

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.96 billion which beat the analyst consensus estimate of $1.95 billion by 0.45 percent. This is a 3.38 percent increase over sales of $1.90 billion the same period last year.

Earnings Beats

FAST

Fastenal Q1 2025 GAAP EPS $0.52, Inline, Sales $1.96B Beat $1.95B Estimate

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) with a Outperform and lowers the price target from $50 to $47.

BSVN

Keefe, Bruyette & Woods Maintains Outperform on Bank7, Lowers Price Target to $47

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and maintains $19 price target.

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported quarterly earnings of $5.07 per share which beat the analyst consensus estimate of $4.62 by 9.74 percent. This is a 14.19 percent increase over earnings of $4.44 per share from the same period last year. The company reported quarterly sales of $46.014 billion which beat the analyst consensus estimate of $44.111 billion by 4.31 percent. This is a 8.15 percent increase over sales of $42.548 billion the same period last year.

JPMorgan Chase Q1 2025 GAAP EPS $5.07 Beats $4.62 Estimate, Sales $46.014B Beat $44.111B Estimate

Wells Fargo Q1 net Interest Income Decreased 6%, Driven By The Impact Of Lower Interest Rates On Floating Rate Assets, Deposit Mix And Pricing Changes, Lower Loan Balances, And One Fewer Day In The Quarter, Partially Offset By Lower Market Funding

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Goldman Sachs analyst Noah Poponak downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109.

Goldman Sachs Downgrades Booz Allen Hamilton to Neutral, Lowers Price Target to $109

Press Releases

Bitdeer Announces Fourth Quarter and Full Year 2024 Earnings Conference Call for February 25, 2025

Bitdeer Announces January 2025 Production and Operations Update

Bitdeer Reports Unaudited Financial Results for the Fourth Quarter and Full Year of 2024

Financing

Bitdeer Announces New US$20,000,000 Share Repurchase Program

Bitdeer Completes Testing of its Latest SEAL03 Bitcoin Mining Chip

Bitdeer Announces February 2025 Production and Operations Update

Bitdeer Launches SEALMINER A2 Pro Bitcoin Mining Machines

Bitdeer AI Innovative Solutions Recognized with a 2025 Artificial Intelligence Excellence Award

SAIHEAT to Provide 40MW Liquid-Cooling Container Solutions to Bitdeer for the Construction of Its New Data Center

Bitdeer Announces March 2025 Production and Operations Update

BTDR

SAIH

SAITW

Agilysys

Amplitude

Cleanspark

Sprinklr

DoubleVerify Holdings

Enfusion

EverCommerce

Exodus Movement, Inc. Class A Common Stock

Exodus Movement

Five9

IREN

Jamf Holding

Karooooo

MeridianLink

NextNav

Opera Limited - American Depositary Shares

Opera

PagerDuty

Pony AI Inc. - American Depositary Shares

Pony AI

D-Wave Quantum

LiveRamp Holdings

Riot Platforms

RingCentral

SEMrush Holdings, Inc. Class A Common Stock

SEMrush Hldgs

Sprout Social, Inc - Class A Common Stock

Sprout Social

Tuya Inc. American Depositary Shares, each representing one Class A Ordinary Share

Tuya

NCR Voyix

Rosenblatt

Needham

Roth MKM

Benchmark

HC Wainwright & Co.

Screenshot 2024-12-17 at 6.40.30 PM

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

NVDA

Bitdeer Shares November Operational Update, Readies For &#34;Transformative&#34; 2025

Screenshot 2024-12-10 at 6.32.01 PM

Bitdeer Technologies Group (NASDAQ: BTDR) Overcame Short-Term Challenges In Q3, Setting Its Sights On The Long Game

Screenshot 2024-11-18 at 7.21.51 PM

Investment Firms AGP, Northland Initiate Coverage On Bitdeer (NASDAQ: BTDR) With Buy Ratings And Targets Close To 100% Higher – What&#39;s Driving The Hype?

Screenshot 2024-11-15 at 7.42.11 PM

FUFU

MARA

RIOT

BitFuFu Posts Double-Digit Third Quarter Revenue Growth In A Challenging Market

Screenshot 2024-10-16 at 5.33.37 PM

Bitdeer (Nasdaq: BTDR) Advances Roadmap With Successful Testing Of Its Energy-Efficient SEAL02 Bitcoin Mining Chip

Screenshot 2024-09-16 at 5.35.19 PM

Amid Volatile Bitcoin Price Landscape, Bitdeer Announces Pricing Of $150 Million Convertible Notes Offering To Fund Continued Growth And Innovation

Screenshot 2024-09-06 at 5.34.09 PM

Bitcoin Miner Bitdeer (NASDAQ: BTDR) Grows Q2 Revenue Amid Volatile Market Backdrop

Screenshot 2024-08-20 at 5.39.14 PM

Bitcoin Miner Bitdeer (NASDAQ: BTDR) Inks Key Partnership, Advances Chip Development, Explores AI Datacenter Expansion

Screenshot 2024-07-24 at 5.39.46 PM

Interview

At The Nexus Of Bitcoin And AI, This Vertically Integrated Miner Has Big News

Screenshot 2024-07-09 at 1.42.12 PM

Bitdeer (NASDAQ: BTDR) Announces Strategic Ohio Land Deal, Expands Power Capacity To 2.5 GW Amid AI And HPC Push

Comments

Bitdeer Technologies

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル